EVs carrying neurotrophic factors, antioxidants, mitochondrial enhancers, or alpha-synuclein-targeting molecules have shown therapeutic effects, reduced neuroinflammation, and improved motor behavior in PD models [129–132]. Here, SNCA is linked to Parkinson disease.